Accelerate Diagnostics (AXDX)
(Delayed Data from NSDQ)
$0.95 USD
+0.01 (1.06%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $0.91 -0.04 (-4.21%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.95 USD
+0.01 (1.06%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $0.91 -0.04 (-4.21%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth C Momentum F VGM
Zacks News
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of -10.20% and 0.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of -2.70% and 20.43%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Codex DNA (DNAY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codex DNA (DNAY) delivered earnings and revenue surprises of 12.50% and 25.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Apollo Endosurgery, Inc. (APEN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apollo Endosurgery, Inc. (APEN) delivered earnings and revenue surprises of -33.33% and 8.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Silk Road Medical (SILK) Stock Jumps 6.7%: Will It Continue to Soar?
by Zacks Equity Research
Silk Road Medical (SILK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Masimo (MASI) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 13.45% and 4.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Alphatec (ATEC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -2.86% and 7.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SeaSpine Holdings (SPNE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of -8.57% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 21.88% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Venus Concept (VERO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Venus Concept (VERO) delivered earnings and revenue surprises of -30% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Avinger (AVGR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Avinger (AVGR) delivered earnings and revenue surprises of -92.56% and 0.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 8.33% and 0.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 23.33% and 3.13%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sensus Healthcare, Inc. (SRTS) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 128.57% and 18.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 57.14% and -11.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Accelerate Diagnostics (AXDX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -2.86% and -12.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics (AXDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for June 2nd
by Zacks Equity Research
BEP, AXDX, FURY, KBAL, and LUNA have been added to the Zacks Rank #5 (Strong Sell) List on June 2, 2021
New Strong Sell Stocks for May 20th
by Zacks Equity Research
AXDX, CRIS, FSTR, GO, and PRLB have been added to the Zacks Rank #5 (Strong Sell) List on May 20, 2021
New Strong Sell Stocks for May 14th
by Zacks Equity Research
AXDX, CDR, FPAY, GCI, and IRTC have been added to the Zacks Rank #5 (Strong Sell) List on May 14, 2021
Accelerate Diagnostics (AXDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -24.24% and -29.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Accelerate Diagnostics (AXDX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Accelerate Diagnostics (AXDX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.